In April 2014, Sun Pharma announced a $3.2-billion deal to acquire Ranbaxy, and the transaction was concluded last year. The employees have held several agitations across cities against the Sun Pharma management over the past few months. Many striking employees with whom Business Standard spoke, said for the past three months, some 500 medical representatives havn’t been paid salaries and travel expenses. The strike is also against Sun Pharmaceutical’s decision to have a uniform structure for paid leave for employees. “As part of the merger between the companies, service rules for the Ranbaxy employees should not have been changed by Sun’s management,” a medical representative said.
In an e-mail response to this newspaper’s query on employees’ agitation, Sun Pharma said that the harmonisation process has been completed. The company did not wish to comment on the issue of compensation to the employees as the matter is sub judice. The matter will now be heard at the Bombay High Court as Sun Pharma challenged the order of the Labour Court of Maharashtra.
Meanwhile, the issue has even reached the Indian Medical Association, which has written to the founder and Managing Director of Sun Pharmaceuticals Dilip Shanghvi, stating service conditions for the erstwhile Ranbaxy medical representatives should be made more suitable. The letter, which has been reviewed by Business Standard, addresses the issue of arbitrary transfer of Ranbaxy medical representatives to other centres as well.
“How will a person who knows only Tamil be able to work in Assam without knowing the local language”, IMA has asked referring to employees’ concerns. In fact, at least 300 medical representatives are learnt to have resigned from the company due to such transfers.
One year after the integration process, the provident fund account is yet to be transferred from the Ranbaxy Charitable Trust, making it difficult for employees to withdraw their PF after leaving the organisation, sources said. Around 4000 employees became part of Sun Pharmaceutical after the integration.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)